Podcast Episodes
Back to Search
Ep. 316 - Trends in Pharma Deals
Season 6 Episode 316
BioCentury’s third annual analysis of pharma company deals finds that bispecifics and degraders are in, cell and gene therapies are out, and China is…
1 year ago
Ep. 315 - China Speed: Data, Deals, First in Class
Season 6 Episode 315
Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converges with We…
1 year ago
Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure
Season 6 Episode 314
Phase III data from Lilly’s orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide use…
1 year ago
Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
Season 6 Episode 313
The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On t…
1 year, 1 month ago
Ep. 312 - Biotech Progress Report
Season 6 Episode 312
A handful of encouraging signals is cause for cautious optimism for biotech headed into the second half of the year — companies have been able to par…
1 year, 1 month ago
Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More
Season 6 Episode 311
This week’s deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportunitie…
1 year, 1 month ago
Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER
Season 6 Episode 310
Last week’s public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene …
1 year, 1 month ago
Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days
Season 6 Episode 309
Chinese biotech is the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation (MFN) pricing po…
1 year, 1 month ago
Ep. 308 - Grand Rounds - Europe Preview
Season 6 Episode 308
There are many reasons why it may be the European biomedical ecosystem’s moment to shine, and advances at the academia-industry interface are a core …
1 year, 1 month ago
Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA
Season 6 Episode 307
Oncology regulation has been less affected by recent changes in FDA leadership than other parts of the agency. On a special sponsored edition of the …
1 year, 2 months ago